



**Egbert F Smit**

**Contact**

Egbert F Smit

## Publications (4)

Gautschi O, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Huret B, Curioni-Fontecedro A, Milia J, Cabarro B, Bluthgen M, Besse B, Smit E, Wolf J, Peters S, Früh M, Koeberle D, Oulkhair Y, Schuler M, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015; 10:1451-7.

Jörger M, Beijnen J, Huitema A, Vincent A, Smits P, Doodeman V, Bard M, Haitjema T, Smit E, Baas P, Burgers S, Schellens J. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. *Cancer* 2011; 118:2466-75.

Buikhuisen W, Burgers J, Vincent A, Schellens J, Beijnen J, Smit E, Jörger M. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. *J Clin Oncol* 2010; 28:e482-3; author reply e484.

Smit E, van Zandwijk N, Vincent A, Schellens J, Jörger M, Dingemans A, Eppinga P, Smit H, Biesma B, Burgers S, Groen H. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2009; 27:2038-45.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)